PDS Biotechnology
PDSB
59 hedge funds and large institutions have $101M invested in PDS Biotechnology in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
51% more call options, than puts
Call options by funds: $4.56M | Put options by funds: $3.03M
28% more funds holding
Funds holding: 46 → 59 (+13)
22% more capital invested
Capital invested by funds: $82.4M → $101M (+$18.2M)
1.78% more ownership
Funds ownership: 21.98% → 23.76% (+1.8%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$5.96M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$4.11M |
| 3 |
Two Sigma Investments
New York
|
+$3.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.59M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$9.05M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$2.13M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.89M |
| 4 |
Renaissance Technologies
New York
|
-$1.12M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $12K | -$2.62K | -210 | -21% |
|
|
CG
52
Cutler Group
San Francisco,
California
| $10K | -$27.7K | -2,220 | -77% |
|
|
TC
53
Truvestments Capital
Sarasota,
Florida
| $10K | – | – | – |
|
54
Federated Hermes
Pittsburgh,
Pennsylvania
| $9K | +$5.85K | +469 | +434% |
|
|
AWA
55
Arkadios Wealth Advisors
Atlanta,
Georgia
| $7K | – | – | – |
|
56
Group One Trading
Chicago,
Illinois
| $3K | +$2.49K | +200 | New |
|
57
Wells Fargo
San Francisco,
California
| $2K | +$299 | +24 | +20% |
|
58
Bank of America
Charlotte,
North Carolina
| $1K | -$1.83K | -147 | -72% |
|
|
IA
59
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
MS
60
Maven Securities
St Helier,
Jersey
| – | -$1.89M | -161,305 | Closed |
|
|
MIM
61
Monashee Investment Management
Boston,
Massachusetts
| – | -$1M | -80,000 | Closed |
|
|
LCM
62
Laurion Capital Management
New York
| – | -$789K | -62,901 | Closed |
|
|
IGGA
63
Iron Gate Global Advisors
Nsl,
Utah
| – | -$316K | -25,239 | Closed |
|
|
6CM
64
683 Capital Management
New York
| – | -$314K | -25,000 | Closed |
|
PDSB Hedge Fund Activity: Q3 2021 in Review
59 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2021, worth a combined $101M — up 22% from $82.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PDSB positions and 6 closed out — a net gain of 13 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $5.96M. The largest seller was AIGH Capital Management, cutting an estimated $9.05M.
- 59 institutional investors held PDS Biotechnology (PDSB) as of Q3 2021, up from 46 in Q2 2021.
- Funds reported $101M of PDS Biotechnology stock for Q3 2021, up 22% quarter-over-quarter.
- 19 funds opened new PDS Biotechnology positions in Q3 2021 and 6 closed out, a net change of +13 holders.
- The largest PDS Biotechnology buyer in Q3 2021 was Two Sigma Advisers, an estimated $5.96M added.
- The largest PDS Biotechnology seller in Q3 2021 was AIGH Capital Management, an estimated $9.05M sold.
Based on aggregated 13F filings for Q3 2021.